27 related articles for article (PubMed ID: 27068253)
1. The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines.
Alileche A; Hampikian G
BMC Cancer; 2017 Aug; 17(1):533. PubMed ID: 28793867
[TBL] [Abstract][Full Text] [Related]
2. EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature.
Yang Y; Zhang B; Li R; Liu B; Wang L
Oncol Lett; 2016 May; 11(5):3546-3550. PubMed ID: 27123149
[TBL] [Abstract][Full Text] [Related]
3. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative, metastatic breast cancer.
Chen XL; Du F; Hong RX; Wang JY; Luo Y; Li Q; Fan Y; Xu BH
Chin J Cancer; 2016 Apr; 35():39. PubMed ID: 27112139
[TBL] [Abstract][Full Text] [Related]
4. Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
Sonnenblick A; de Azambuja E; Agbor-Tarh D; Bradbury I; Campbell C; Huang Y; Dueck AC; Pritchard KI; Wolff AC; Jackisch C; Lang I; Untch M; Smith I; Boyle F; Xu B; Gomez H; Perez EA; Piccart M; Azim HA
J Natl Cancer Inst; 2016 Aug; 108(8):. PubMed ID: 27098150
[TBL] [Abstract][Full Text] [Related]
5. T-DM1 Combo Graduates from I-SPY 2.
Cancer Discov; 2016 Jun; 6(6):OF5. PubMed ID: 27095360
[TBL] [Abstract][Full Text] [Related]
6. Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities.
Jonas O; Oudin MJ; Kosciuk T; Whitman M; Gertler FB; Cima MJ; Flaherty KT; Langer R
Clin Cancer Res; 2016 Dec; 22(24):6031-6038. PubMed ID: 27091406
[TBL] [Abstract][Full Text] [Related]
7. CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma.
An R; Wang Y; Voeller D; Gower A; Kim IK; Zhang YW; Giaccone G
Oncotarget; 2016 May; 7(20):29199-210. PubMed ID: 27078848
[TBL] [Abstract][Full Text] [Related]
8. Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Awada A; Colomer R; Inoue K; Bondarenko I; Badwe RA; Demetriou G; Lee SC; Mehta AO; Kim SB; Bachelot T; Goswami C; Deo S; Bose R; Wong A; Xu F; Yao B; Bryce R; Carey LA
JAMA Oncol; 2016 Dec; 2(12):1557-1564. PubMed ID: 27078022
[TBL] [Abstract][Full Text] [Related]
9. Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models.
Hapuarachchige S; Kato Y; Artemov D
Sci Rep; 2016 Apr; 6():24298. PubMed ID: 27068794
[TBL] [Abstract][Full Text] [Related]
10. Intron-Encoded Domain of Herstatin, An Autoinhibitor of Human Epidermal Growth Factor Receptors, Is Intrinsically Disordered.
Tashiro D; Suetaka S; Sato N; Ooka K; Kunihara T; Kudo H; Inatomi J; Hayashi Y; Arai M
Front Mol Biosci; 2022; 9():862910. PubMed ID: 35573740
[TBL] [Abstract][Full Text] [Related]
11. Strategic Decoy Peptides Interfere with MSI1/AGO2 Interaction to Elicit Tumor Suppression Effects.
Yang YP; Lee AC; Lin LT; Chen YW; Huang PI; Ma HI; Chen YC; Lo WL; Lan YT; Fang WL; Wang CY; Liu YY; Hsu PK; Lin WC; Li CP; Chen MT; Chien CS; Wang ML
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158774
[TBL] [Abstract][Full Text] [Related]
12. The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4.
Lv M; Qiao C; Jiang N; Li X; Yu M; Hou C; Li Y; Feng J; Shen B
Mol Biotechnol; 2012 Jun; 51(2):174-82. PubMed ID: 22139885
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design of peptides against G3BP with cytotoxicity on tumor cells.
Cui W; Wei Z; Chen Q; Cheng Y; Geng L; Zhang J; Chen J; Hou T; Ji M
J Chem Inf Model; 2010 Mar; 50(3):380-7. PubMed ID: 20180532
[TBL] [Abstract][Full Text] [Related]
14. Discovery of new human epidermal growth factor receptor-2 (HER2) inhibitors for potential use as anticancer agents via ligand-based pharmacophore modeling.
Zalloum H; Tayyem R; Irmaileh BA; Bustanji Y; Zihlif M; Mohammad M; Rjai TA; Mubarak MS
J Mol Graph Model; 2015 Sep; 61():61-84. PubMed ID: 26188796
[TBL] [Abstract][Full Text] [Related]
15. Design of small molecules targeting I-BAR proteins.
Cao M; Chang W; Zheng M; Xie L; Zhang Y; Cai J; Chen J; Zhan X; Ji M; Gu N
Curr Pharm Des; 2015; 21(10):1318-26. PubMed ID: 25410498
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of peptides against HER2 with cytotoxicity on colon cancer.
Cha N; Han X; Jia B; Liu Y; Wang X; Gao Y; Ren J
Artif Cells Nanomed Biotechnol; 2017 May; 45(3):649-654. PubMed ID: 27068253
[TBL] [Abstract][Full Text] [Related]
17. Comparison of patient-derived high and low phosphatidylserine-exposing colorectal carcinoma cells in their interaction with anti-cancer peptides.
Wilms D; Andrä J
J Pept Sci; 2017 Jan; 23(1):56-67. PubMed ID: 28066958
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
